Vistagen director Paul Edick resigns from board

Vistagen Therapeutics, Inc. reported that on February 13, 2026, board member Paul Edick resigned from its Board of Directors.

Rhea-AI Filing Summary

Vistagen Therapeutics, Inc. reported that on February 13, 2026, board member Paul Edick resigned from its Board of Directors. The company did not provide additional details about the circumstances of his resignation.

The company stated that it is actively seeking new candidates to fill the resulting vacancy on the Board, indicating its intention to maintain a full board composition.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Vistagen Therapeutics (VTGN) disclose in this 8-K filing?

Vistagen Therapeutics disclosed that Board member Paul Edick resigned on February 13, 2026. The company also noted that it is actively seeking new candidates to fill the resulting vacancy on its Board of Directors.

When did Vistagen Therapeutics (VTGN) director Paul Edick resign from the Board?

Director Paul Edick resigned from the Board of Vistagen Therapeutics on February 13, 2026. This date is specified as the effective resignation date in the company’s current report on Form 8-K.

How is Vistagen Therapeutics (VTGN) responding to the Board vacancy created by the resignation?

Vistagen Therapeutics stated it is actively seeking new candidates to fill the Board vacancy created by Paul Edick’s resignation. This indicates the company’s intention to restore its Board to full strength following the director’s departure.

Does the Vistagen Therapeutics (VTGN) filing mention any changes to executive management roles?

The filing identifies Shawn K. Singh as President and Chief Executive Officer signing on behalf of the company. It does not describe any changes to his roles, focusing instead on the resignation of director Paul Edick from the Board.

What stock exchange lists Vistagen Therapeutics (VTGN) common stock?

Vistagen Therapeutics’ common stock, with a par value of $0.001 per share, is listed on the Nasdaq Capital Market. The company’s trading symbol on this exchange is VTGN, as referenced in the filing’s securities registration section.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/20/2026 - 09:12 AM EST Learn about SEC filing dates

FALSE000141168500014116852024-09-232024-09-23

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 13, 2026

Vistagen Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Nevada			000-54014			20-5093315
(State or other jurisdiction of incorporation)			(Commission File Number)			(IRS Employer Identification Number)

343 Allerton Ave.

South San Francisco, California 94080

(Address of principal executive offices)

(650) 577-3600

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.001 per share			VTGN			Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2)

Emerging Growth Company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act o

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.

On February 13, 2026, Paul Edick resigned from the Board of Directors (the “Board”) of Vistagen Therapeutics, Inc. (the “Company”). The Company is actively seeking new candidates to fill the resulting vacancy on the Board.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			Vistagen Therapeutics, Inc.
Date: February 20, 2026			By:			/s/ Shawn K. Singh
						Shawn K. Singh President and Chief Executive Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.7 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 21.1 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.2 KB